AbbVie | ABBV - Assets


AbbVie reported $135.12B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Abbott USD 110.43B 23.72B Mar/2026
ALKERMES USD 4.39B 135.05M Jun/2026
Amgen USD 92.5B 1.92B Mar/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Eisai JPY 1.56T 108.98B Jun/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
J&J USD 201.06B 167M Jun/2026
Medtronic USD 91.48B 139M Dec/2025
Merck USD 128.68B 8.18B Mar/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Pacira USD 1.21B 56.38M Mar/2026
Perrigo USD 7.98B 551.9M Mar/2026
Pfizer USD 201.13B 6.49B Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026
UCB EUR 18.16B 971M Dec/2025
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
United Therapeutics USD 6.71B 1.17B Mar/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026
Zoetis USD 15.15B 313M Mar/2026